What is the current valuation of AstraZeneca’s Rilvegostomig
The revenue for Rilvegostomig is expected to reach an annual total of $55 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Rilvegostomig Overview
Rilvegostomig (AZD-2936) is under development for the treatment of solid tumors, advanced or metastatic squamous or non-squamous non-small cell lung carcinoma, squamous or non-squamous non-small cell lung cancer, head and neck squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hepatocellular carcinoma, hypopharyngeal cancer, laryngeal cancer and locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, cholangiocarcinoma and gallbladder cancer. It is administered by intravenous route. The therapeutic candidate is a bi-specific monoclonal antibody acts by targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT) and programmed cell death protein 1 (PD1). It is derived from COM902 (anti-TIGIT antibody). It is administered through Intravenous route.
AstraZeneca Overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$44,351 million for the fiscal year ended December 2022 (FY2022), an increase of 18.5% over FY2021. In FY2022, the company’s operating margin was 8.5%, compared to an operating margin of 2.8% in FY2021. In FY2022, the company recorded a net margin of 7.4%, compared to a net margin of 0.3% in FY2021.
The company reported revenues of US$11,492 million for the third quarter ended September 2023, an increase of 0.7% over the previous quarter.
For a complete picture of Rilvegostomig’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#current #valuation #AstraZenecas #Rilvegostomig